Introduction: Diffuse non-Hodgkin lymphoma (NHL) is a hematologic neoplasm characterized by high incidence and growing public health impact. In Brazil, NHL comprises a substantial share of lymphoid malignancies, with marked regional disparities. In the Northern Region, particularly Pará, access to early diagnosis and accurate subtype classification remains limited. Objectives: To analyze temporal trends and demographic patterns of mortality due to diffuse non-Hodgkin lymphoma (ICD-10 C83) in Pará between 2019 and 2023, identifying gaps in diagnostic services, access to care, and subtype reporting. Methods: This is an epidemiological, descriptive and retrospective study based on mortality data from diffuse non-Hodgkin’s lymphoma (ICD10 C83) in Pará. The data were obtained from the Mortality Information System (SIM) via TABNET/DATASUS, covering the period from 2019 to 2023. The variables analyzed were: Year of death (2019-2023); Age group (20 to 79 years); Sex (male and female); Color/race (White, Black, Brown, Yellow and Indigenous); Place of occurrence (hospital, home, public road and other health establishments); and Lymphoma subtype classified according to ICD-10 codes, which are C83 (diffuse non-Hodgkin lymphoma), C84 (cutaneous and peripheral T-cell lymphomas) and C85 (other types of non-Hodgkin lymphoma and unspecified types). Results: Between 2019 and 2023, 294 deaths from non-Hodgkin lymphomas were recorded in the state of Pará, considering individuals aged 20 to 79 years. Category C85 was the most prevalent, totaling 216 deaths (73.5%), followed by category C83, with 65 cases (22.1%), and C84, with 13 deaths (4.4%). There was also an upward trend in the total number of deaths over the five years analyzed: from 56 in 2019 to 73 in 2023, representing an increase of approximately 30%. Category C85 remained the main cause of death from lymphoma in all years, with a significant increase in 2023, which represented 56 deaths in this category alone. In relative terms, lymphomas classified as C83 and C84 showed variable proportions between years, with an increase in category C83 – Diffuse nonHodgkin’s lymphoma in 2023 (20.5%) and slight fluctuation in category C84, which maintained low proportions in all years analyzed. The analysis of the subgroups revealed that most deaths occurred in individuals aged between 60 and 69 years, in addition to a predominance of males and brown skin color, in accordance with the demographic pattern of the population of Pará. These findings suggest not only a trend of progressive increase in mortality from diffuse non-Hodgkin lymphomas in Pará, but also indicate possible difficulties in diagnostic classification, evidenced by the high proportion of non-Hodgkin lymphomas in the state. Conclusion: The rising mortality from diffuse NHL in Pará, especially among individuals aged 20–79 years, highlights the need to improve diagnostic accuracy, early detection, and access to effective treatment. The high proportion of unspecified subtypes (C85) points to gaps in pathology services, possibly due to limited use of immunophenotyping and molecular tools. These trends may also reflect delayed diagnoses and restricted access to care in underserved areas, underscoring structural weaknesses in the local healthcare system that demand targeted interventions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
